Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 16, 2006. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons regarding the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory notification of share transactions and does not contain financial performance data.
Material Changes
On November 15, 2006, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("the GSK Trust"), transferred 33,590 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of these transactions on November 16, 2006.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) hold interests in the shares held by the GSK Trust in the same capacity as other employees.
Key Facts for Investor Verification
- Transaction Type: Transfer of 33,590 Ordinary Shares from the GSK Trust to employee plan participants.
- Involved Parties: Abacus (GSK) Trustees Limited and participants of the SmithKline Beecham Employee Share Option Plan 1991.
- Director Interest: Directors Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop have indirect interests in the trust shares.
- Regulatory Basis: Notification made in accordance with Disclosure Rule 3.1.4R(1)(b).